Abscint

Executive Summary

Abscint is a Belgian clinical-stage biotechnology company developing precision diagnostic imaging agents for oncology. Its platform leverages single-domain antibodies (sdAbs) labeled with radioisotopes to create novel PET tracers that enable non-invasive, whole-body visualization of specific cancer targets. The lead program targets HER2 expression in breast cancer and other solid tumors, addressing a critical need for accurate, real-time assessment of HER2 status to guide therapy selection. By providing whole-body imaging, Abscint’s technology has the potential to improve patient stratification, monitor treatment response, and detect metastases earlier than current standard-of-care methods. The company is advancing its lead candidate through early clinical development, with initial clinical data expected to demonstrate proof-of-concept in HER2-positive cancers. If successful, Abscint could offer a more precise and less invasive diagnostic alternative to tissue biopsies, thereby enabling more personalized treatment decisions. The platform’s versatility also positions it to expand into other cancer targets through its sdAb library. Given the growing emphasis on precision oncology and the increasing use of PET imaging, Abscint’s approach holds significant commercial potential, though it remains at an early stage with typical development risks.

Upcoming Catalysts (preview)

• TBDFirst-in-human data for lead HER2-targeting PET tracer30% success
• TBDInitiation of a pivotal trial for lead diagnostic20% success
• TBDStrategic partnership or licensing deal with a pharmaceutical company25% success